Result of AGM

RNS Number : 0903H
Tissue Regenix Group PLC
14 June 2013
 

 

 

Tissue Regenix Group plc

 

Result of AGM

 

YORK, 14 June, 2013 - Tissue Regenix Group plc ("Tissue Regenix" or "the Group") (AIM:TRX), the regenerative medical devices company, hereby provides notification that, at the Group's AGM held earlier today, all resolutions were duly proposed to shareholders and passed.

 

For additional information please contact:

 

Tissue Regenix Group plc

+44 (0)1904 435 176

Antony Odell, Managing Director

Ian Jefferson, Chief Financial Officer




Jefferies International Ltd.

+44 (0)20 7029 8000

Simon Hardy

Harry Nicholas




Newgate Communications

+44 (0)20 7680 6550

Alistair Kellie

Andrew Jones


 

 

 

About Tissue Regenix

 

Tissue Regenix (AIM: TRX) is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the world.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGSFUFFLFDSEDM
UK 100

Latest directors dealings